Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adolescent Results Put Pfizer/BioNTech Ahead Of COVID Vaccine Pack, For Now

Hoping For EUA Before Start Of School Year

Executive Summary

An EUA would carve out a market advantage, although Moderna should be releasing similar data soon for its COVID-19 vaccine.

You may also be interested in...



Coronavirus Update: Pfizer/BioNTech Vaccine Shows Six-Month, Variant Protection

The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.

BioNTech Expands COVID-19 Vaccine Output Again, Forecasts $10bn Revenues

Success of the vaccine will fuel the company’s push into immunotherapy, as it reported first commercial sales.

COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies

A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel